Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease
Authors:
- Balpreet MatharuBMBalpreet Matharu
- Omar El-AgnafOEOmar El-Agnaf
- Amna RazviARAmna Razvi
- Brian M. AustenBABrian M. Austen
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Galantamine inhibits β-amyloid aggregation and cytotoxicityJournal of the Neurological Sciences, 2009
- Designing Peptide Inhibitors for Oligomerization and Toxicity of Alzheimer's β-Amyloid PeptideBiochemistry, 2008
- Physiological and Biophysical Factors That Influence Alzheimer’s Disease Amyloid Plaque Targeting of Native and Putrescine Modified Human Amyloid β40The Journal of Pharmacology and Experimental Therapeutics, 2006
- 3D structure of Alzheimer's amyloid-β(1–42) fibrilsProceedings of the National Academy of Sciences, 2005
- Direct Quantification of Analyte Concentration by Resonant Acoustic ProfilingClinical Chemistry, 2005
- Design of Peptidyl Compounds That Affect β-Amyloid Aggregation: Importance of Surface Tension and ContextBiochemistry, 2005
- Therapeutic approaches to protein-misfolding diseasesNature, 2003
- Oligomerization and Toxicity of β-Amyloid-42 Implicated in Alzheimer's DiseaseBiochemical and Biophysical Research Communications, 2000
- Protected peptide p-nitroanilides by solid-phase synthesisLetters in Peptide Science, 2000
- On the concept of linear modified retro-peptide structuresAccounts of Chemical Research, 1979